Six-Week Blarcamesine Restores Motor Function and Nerve Fiber Growth in Parkinson’s Model
Anavex’s blarcamesine fully rescued impaired motor function and stimulated dopaminergic nerve fiber regrowth in the striatum after six weeks in an advanced dual-hit Parkinson’s disease model. The preclinical study combined alpha-synuclein pathology with noradrenergic degeneration, demonstrating potential disease-modifying effects for early Parkinson’s therapy.
1. Preclinical Study Results
Six weeks of oral blarcamesine fully restored impaired motor function and increased dopaminergic nerve fiber density in the striatum of a rodent Parkinson’s model. Complete motor rescue and significant fiber regrowth were observed, underscoring blarcamesine’s potential to reverse key neurodegenerative features.
2. Advanced Parkinson’s Model
The study utilized a dual-hit rodent model combining alpha-synuclein accumulation with noradrenergic degeneration to replicate core aspects of Parkinson’s pathology. This approach allowed direct evaluation of blarcamesine’s impact on both protein aggregation and neuron loss.
3. Implications and Next Steps
These data support advancing blarcamesine as a disease-modifying candidate in early Parkinson’s clinical trials. Anavex plans to use these findings in regulatory discussions and to design Phase 2 studies, leveraging insights from its Alzheimer’s program to explore broader CNS applications.